Interestingly, endogenous NE inhibitors, like SERPINB1, are down-regulated in early and advanced prostate cancer, which is indicative of another strategy to establish high NE activity in tumours (41, 47). The gene discussed is ELANE; the disease is Familial prostate cancer.